Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

Arianna Huffington's Thrive Global aims to help people build healthy habits. Today, the company announced a partnership with a Fortune 500 pharma giant that make ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

LCCI Hyderabad will focus on scaling up Lilly’s innovation and efficiency by unlocking new technological advancements ...

The GCC, to be known as the Lilly Capability Centre India (LCCI), will be the company’s second centre in the country, ...

Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world ...

According to our calculations, a $1000 investment made in January 2015 would be worth $3,848.25, or a 284.82% gain, as of January 9, 2025. Investors should keep in mind that this return excludes ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...